文献速递临床试验与 GCP

奥美卡替麦考比尔对射血分数降低的慢性心力衰竭患者运动能力的影响:METEORIC-HF随机临床试验

Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

METEORIC-HF是一项3期双盲安慰剂对照随机试验,纳入276例射血分数≤35%、NYHA II-III级、NT-proBNP≥200 pg/mL且基线峰值摄氧量≤预测值75%的慢性HFrEF患者,按2:1随机接受奥美卡替麦考比尔(n=185)或安慰剂(n=91)治疗20周。主要终点峰值摄氧量变化两组无显著差异(最小二乘均值差-0.45 mL/kg/min,95%CI -1.02至0.13,P=0.13)。结论认为奥美卡替麦考比尔未显著改善运动能力,不支持用于改善HFrEF患者运动能力。

要点

  • 在慢性HFrEF患者中,奥美卡替麦考比尔治疗20周未显著改善峰值摄氧量。
  • 峰值摄氧量最小二乘均值差为-0.45 mL/kg/min(95%CI -1.02至0.13;P=0.13)。
  • 不良事件包括头晕、疲劳、心力衰竭事件、死亡、卒中和心肌梗死。

核心结论

  • 在慢性HFrEF患者中,与安慰剂相比,奥美卡替麦考比尔治疗20周未显著改善运动能力。
  • 这些发现不支持使用奥美卡替麦考比尔治疗HFrEF以改善运动能力。

研究设计与样本

  • 3期双盲安慰剂对照随机试验,纳入HFrEF(左心室射血分数≤35%)、NYHA II-III级症状、NT-proBNP≥200 pg/mL且基线峰值摄氧量≤预测值75%的患者。
  • 2019年3月至2021年5月在北美和欧洲63个中心按2:1随机分配至奥美卡替麦考比尔(n=185)或安慰剂(n=91),末次患者访视为2021年11月29日。
  • 干预为口服奥美卡替麦考比尔或匹配安慰剂,每日两次,根据目标血浆水平给予25 mg、37.5 mg或50 mg,持续20周。
  • 共276例患者随机(中位年龄64岁;IQR 55-70岁;女性42例[15%]),249例(90%)完成试验。

主要发现

  • 奥美卡替麦考比尔组基线峰值摄氧量中位数为14.2 mL/kg/min(IQR 11.6-17.4),安慰剂组为15.0 mL/kg/min(IQR 12.0-17.2)。
  • 峰值摄氧量平均变化两组无显著差异(奥美卡替麦考比尔组-0.24 mL/kg/min vs 安慰剂组0.21 mL/kg/min;最小二乘均值差-0.45 mL/kg/min[95%CI -1.02至0.13];P=0.13)。
  • 不良事件包括头晕(奥美卡替麦考比尔组4.9% vs 安慰剂组5.5%)、疲劳(4.9% vs 4.4%)、心力衰竭事件(4.9% vs 4.4%)。
  • 死亡(奥美卡替麦考比尔组1.6% vs 安慰剂组1.1%)、卒中(0.5% vs 1.1%)、心肌梗死(0% vs 1.1%)。

临床怎么用

  • 原文结论指出,这些发现不支持使用奥美卡替麦考比尔治疗HFrEF以改善运动能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF) but is not consistently improved by any of the current guideline-directed medical therapies. OBJECTIVE: To determine whether omecamtiv mecarbil, a novel direct myosin activator that improves cardiac performance and reduces the risk for cardiovascular death or first HF event in HFrEF, can improve peak exercise capacity in patients with chronic HFrEF. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, double-blind, placebo-controlled randomized trial of patients with HFrEF (left ventricular ejection fraction ≤35%), New York Heart Association class II-III symptoms, N-terminal pro-B-type natriuretic peptide level of 200 pg/mL or greater, and baseline peak oxygen uptake (V̇o2) of 75% or less of predicted. Patients were randomized in a 2:1 ratio (omecamtiv mecarbil to placebo) between March 2019 and May 2021 at 63 sites in North America and Europe, with the last patient visit occurring on November 29, 2021. INTERVENTIONS: Omecamtiv mecarbil (n = 185) or matching placebo (n = 91), given orally twice daily at a dose of 25 mg, 37.5 mg, or 50 mg based on target plasma levels, for 20 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was a change in exercise capacity (peak V̇o2) from baseline to week 20. Secondary end points included total workload, ventilatory efficiency, and daily physical activity as determined by accelerometry. RESULTS: Among 276 patients who were randomized (median age, 64 years; IQR, 55-70 years; 42 women [15%]), 249 (90%) completed the trial. The median left ventricular ejection fraction was 28% (IQR, 21-33) and the median baseline peak V̇o2 was 14.2 mL/kg/min (IQR, 11.6-17.4) in the omecamtiv mecarbil group and 15.0 mL/kg/min (IQR, 12.0-17.2) in the placebo group. Mean change in peak V̇o2 did not differ significantly between the omecamtiv mecarbil and placebo groups (mean, -0.24 mL/kg/min vs 0.21 mL/kg/min; least square mean difference, -0.45 mL/kg/min [95% CI, -1.02 to 0.13]; P = .13). Adverse events included dizziness (omecamtiv mecarbil: 4.9%, placebo: 5.5%), fatigue (omecamtiv mecarbil: 4.9%, placebo: 4.4%), heart failure events (omecamtiv mecarbil: 4.9%, placebo: 4.4%), death (omecamtiv mecarbil: 1.6%, placebo: 1.1%), stroke (omecamtiv mecarbil: 0.5%, placebo: 1.1%), and myocardial infarction (omecamtiv mecarbil: 0%, placebo: 1.1%). CONCLUSIONS AND RELEVANCE: In patients with chronic HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. These findings do not support the use of omecamtiv mecarbil for treatment of HFrEF for improvement of exercise capacity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03759392.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lewis GD, Voors AA, Cohen-Solal A, et al. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. JAMA. 2022. PMID: 35852527. doi:10.1001/jama.2022.11016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。